<DOC>
	<DOCNO>NCT00826371</DOCNO>
	<brief_summary>The purpose study provide efficacy safety data monthly ranibizumab 0.5 mg intravitreal injection Chinese patient subfoveal choroidal neovascularization ( CNV ) secondary age-related macular degeneration ( AMD ) . The study result support regulatory submission China make ranibizumab available clinical use .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Once Monthly Ranibizumab Injections Chinese Patients With Wet Age Related Macular Degeneration ( AMD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female Chinese patient 50 year age great . Patients primary recurrent subfoveal CNV secondary AMD . Patients BCVA score 73 24 character study eye . Active , history , ocular inflammation infection study eye within last 30 day . Uncontrolled glaucoma study eye . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>AMD</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>